rs104894362
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_004985.5(KRAS):c.468C>G(p.Phe156Leu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Consequence
KRAS
NM_004985.5 missense
NM_004985.5 missense
Scores
8
6
1
Clinical Significance
Conservation
PhyloP100: 6.22
Genes affected
KRAS (HGNC:6407): (KRAS proto-oncogene, GTPase) This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a chain GTPase KRas, N-terminally processed (size 184) in uniprot entity RASK_HUMAN there are 29 pathogenic changes around while only 0 benign (100%) in NM_004985.5
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.952
PP5
Variant 12-25209894-G-C is Pathogenic according to our data. Variant chr12-25209894-G-C is described in ClinVar as [Pathogenic]. Clinvar id is 12595.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KRAS | NM_004985.5 | c.468C>G | p.Phe156Leu | missense_variant | 5/5 | ENST00000311936.8 | NP_004976.2 | |
KRAS | NM_033360.4 | c.*22C>G | 3_prime_UTR_variant | 6/6 | ENST00000256078.10 | NP_203524.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KRAS | ENST00000311936.8 | c.468C>G | p.Phe156Leu | missense_variant | 5/5 | 1 | NM_004985.5 | ENSP00000308495 | P4 | |
KRAS | ENST00000256078.10 | c.*22C>G | 3_prime_UTR_variant | 6/6 | 1 | NM_033360.4 | ENSP00000256078 | A1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome Cov.: 30
GnomAD4 exome
Cov.:
30
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Cardiofaciocutaneous syndrome 2 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 2008 | - - |
KRAS-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 29, 2023 | The KRAS c.468C>G variant is predicted to result in the amino acid substitution p.Phe156Leu. This variant has been reported in patients diagnosed with Costello syndrome (Patient 12 in Zenker et al. 2007. PubMed ID: 17056636), Noonan syndrome (Patient 24 in Table S4 in Bessis et al. 2019. PubMed ID: 30417923; Supplementary Table 1 in Li et al. 2019. PubMed ID: 31219622) and as de novo in a patient with cardio-facio-cutaneous (Søvik et al. 2009. PubMed ID: 21686750). Functional studies showed that this variant led to an increase in GDP/GTP exchange and a reduction in GAP-stimulated GTPase rates (Gremer et al. 2011. PubMed ID: 20949621; Schubbert et al. 2007. PubMed ID: 17875937 ). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. In addition another variant impacting the same amino acid residue (p.Phe156Ile) has been documented in a patient with a KRAS-related disorder (Patient 11 in Zenker et al. 2007. PubMed ID: 17056636). Based on this evidence, the c.468C>G (p.Phe156Leu) variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 19, 2017 | Heterozygous for the F156L mutation in the KRAS gene, consistent with the diagnosis of a disorder in the Noonan syndrome spectrum.p.Phe156Leu (TTC>TTG):c.468 C>G in exon 5 of the KRAS gene (NM_004985.3)The F156L missense mutation in the KRAS gene has been reported previously in a 14 month old male who was diagnosed with Costello syndrome with hypertrophic cardiomyopathy, ASD and pulmonic stenosis, developmental delay, and mild-moderate mental retardation, failure to thrive, severe feeding difficulties, loose and redundant skin with deep palmar and plantar creases, Dandy-Walker malformation, and facial dysmorphism (Zenker et al., 2007). Another missense mutation of the same codon, F156I, was described in a patient with features of both Noonan and CFC syndrome (Zenker et al., 2007). Additionally, functional in vitro studies have demonstrated that the F156L mutation results in profound activation of the MAPK pathway (Gremer et al, 2011). The variant is found in NOONAN panel(s). - |
RASopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 31, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Uncertain
D
MutationTaster
Benign
A;A;A
PROVEAN
Pathogenic
D;N
REVEL
Pathogenic
Sift
Uncertain
D;D
Sift4G
Pathogenic
D;D
Polyphen
D;.
Vest4
MutPred
Gain of catalytic residue at V152 (P = 0.1003);.;
MVP
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at